JASON ROBERT WESTIN to Intention to Treat Analysis
This is a "connection" page, showing publications JASON ROBERT WESTIN has written about Intention to Treat Analysis.
Connection Strength
0.034
-
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.
Score: 0.034
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.